Meeting
2014 Genitourinary Cancers Symposium
Tumor-directed PET imaging of bone metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled anti-prostate specific membrane antigen (PSMA) antibody J591.
Authors
Michael J. Morris
Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY
Michael J. Morris , Neeta Pandit-Taskar , Scott T. Tagawa , David M. Nanus , Stephen Barnett Solomon , Jorge A. Carrasquillo , Victor E. Reuter , Jason Stuart Lewis , Volkan Beylergil , Joseph A. O' Donoghue , Serge K. Lyashchenko , Danny F. Martinez , Kristen Rebecca Curtis , Jeremy C. Durack , Sarah M. Cheal , Neil Harrison Bander , Howard I. Scher , Steven M. Larson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT01543659
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 25)
DOI
10.1200/jco.2014.32.4_suppl.25
Abstract #
25
Poster Bd #
B9
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Tumor-directed PET imaging of metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled antiprostate-specific membrane antigen (PSMA) antibody J591.
First Author: Jarett L. Feldman
Poster
2015 Genitourinary Cancers Symposium
Tumor-directed PET imaging of metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled antiprostate-specific membrane antigen (PSMA) antibody J591.
First Author: Jarett L. Feldman
Poster
2013 Genitourinary Cancers Symposium
Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Michael J. Morris
Poster
2024 ASCO Genitourinary Cancers Symposium
Prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Frederic Pouliot